Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows a new site revision note (Revision: v3.4.2) and removes an older funding-status warning and Revision: v3.4.1; these are maintenance updates rather than changes to the trial details or data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a government funding lapse notice informing users that information may not be up to date and linking to cc.nih.gov and opm.gov for status updates. The page now shows Revision: v3.4.1, replacing the previous v3.4.0.SummaryDifference0.5%

- Check28 days agoChange DetectedShow glossary was added and QC-related metadata was updated (Last Update Submitted that Met QC Criteria and Revision: v3.4.0). The previous labels Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded a 'Locations' section with an 'Arizona' entry and removed the separate 'Arizona Locations' heading, altering how study sites are displayed.SummaryDifference0.2%

- Check92 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; no impact on study content or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.